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Abstract
BACKGROUND. In order to evaluate the functional capacity of
the liver by means of clearance determination, the derivative of
iminodiacetic acid (99mTc-HEPIDA) has been used in recent de-
cades. Because of recent problems with manufacturing and
delivery of 99mTc-HEPIDA, an investigation was undertaken with
the aim of testing whether a more widely available 99mTc-MBrIDA
could be used for clearance determination and whether hepatic
clearance measured with the use of this compound provides
a similarly useful test of hepatic function.
MATERIAL AND METHODS. Comparative investigations were
performed in 73 patients of both sexes. The state of the efficien-
cy of liver parenchyma was determined based on seven widely
used biochemical tests, i.e. levels of: bilirubin, albumin, and
gamma globulin; activity of AST, ALT, GGTP, and prothrombin
index. The clearances of both radiopharmaceuticals, 99mTc-HEP-
IDA and 99mTc-MBrIDA, were determined by means of multisam-
Comparison of 99mTc-HEPIDA
and 99mTc-MBrIDA from the standpoint
of hepatic clearance determination
— preliminary communication
Correspondence to: Marian J. Surma
Department of Nuclear Medicine, Medical University of Lodz
ul. Czechoslowacka 8–10, 92–0216 Lodz, Poland
Tel: (+48) 42 678 36 84, fax: (+48) 42 675 72 85
e-mail: mjsurma@csk.umed.lodz.pl, marian.surma@umed.lodz.pl
ple technique. The results of determination were correlated
among themselves and with the results of biochemical tests.
The set of results of all estimations allowed a factorial analysis
to be performed to find a common factor and to compute the
values of factor loadings in particular tests.
RESULTS. Obvious correlation between plasma and hepatic
clearances of both radiopharmaceuticals was obtained and be-
tween plasma clearance of 99mTc-MBrIDA and hepatic clearance
of 99mTc-HEPIDA. Correlation coefficients of 99mTc-MBrIDA clear-
ance and the biochemical test results attained somewhat lower
values than for 99mTc-HEPIDA clearance. Similarly, values of c2
test of independence of 99mTc-MBrIDA clearances and test re-
sults were also less close than for 99mTc-HEPIDA clearances.
Factorial analysis showed that common factor loading is great-
est for hepatic clearance of 99mTc-HEPIDA; the values of two load-
ings of 99mTc-MBrIDA clearances are very close, but somewhat
lower than those for 99mTc-HEPIDA.
CONCLUSIONS. From the performed investigations it is possi-
ble to conclude that 99mTc-MBrIDA clearances may be used for
the evaluation of liver parenchyma performance, even if the re-
sults may not be as certain as those obtained using 99mTc-HEP-
IDA.
Key words: 99mTc-HEPIDA clearances, 99mTcMBrIDA clearan-
ces, hepatic capacity measurements
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Introduction
The derivatives of iminodiacetic acid (IDA) labelled with 99mTc
have been used for decades for dynamic studies of the biliary
system. Six derivatives fulfil the demands expected from clini-
cally useful radiopharmaceuticals [1]. The most common two
substances: 99mTc-MBrIDA (99mTc-N-(3-bromo-2, 4, 6, trimethy-
lacetanilide) and 99mTc-HEPIDA [99mTc-N-(2, 4 dimethylacetanil-
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ide) iminodiacetic acid] have also been used for the evaluation
of the functional capacity of the liver by means of clearance stud-
ies [2–4, 9–11].
The derivatives of IDA are picked up from the blood and elim-
inated with bile to the intestines. A disadvantage of 99mTc-HEPI-
DA, where clearance determinations are concerned, lies in the
fact that variable fraction of the compound is excreted with urine.
To obtain a meaningful result, when hepatic clearance of the ra-
diopharmaceuticals is required, a urinary clearance has to be
determined in parallel. Therefore, the procedure became more
laborious and susceptible to larger errors because hepatic clear-
ance can be obtained only by subtracting the urinary component
from the total plasma clearance. However, the hepatic clearance
measured in this way was shown to be a reliable clinical test for
the assessment of the functional capacity of the liver [9–11]. The
results of 99mTc-HEPIDA clearance determination provide useful
data for classification of the degree of liver function impairment
and can be used for monitoring hepatic function. However, there
have recently been problems with the manufacture and delivery
of 99mTc-HEPIDA.
The present investigation was undertaken with the aim of test-
ing whether a widely available 99mTc-MBrIDA could be used for he-
patic clearance determinations and whether hepatic clearance
measured with the use of this compound could provide a similarly
useful test of hepatic function.
Materials and methods
The 99mTc-MBrIDA was purchased from the Radioisotope
Centre POLATOM. To determine whether this radiopharmaceu-
tical could be a useful substitute for 99mTc-HEPIDA, clearance
determinations were made using both substances, and both
plasma and urinary clearances were measured. The results were
compared to each other and were juxtaposed to biochemical
tests widely used for the assessment of liver parenchyma func-
tion.
Group of investigated patients
The investigations were made on 73 patients of both sexes,
with age varying between 20.5 and 77.1 years (mean 52 years). In
all subjects a clinical diagnosis of chronic hepatitis of varying etiol-
ogy had been established, with a wide range of functional impair-
ment of the organ. These patients were directed to the Depart-
ment of Nuclear Medicine for diagnostic reasons; however, the
second determination of the clearance was made for research
purposes. The plans and justification for the latter were submitted
for consideration to the Regional Ethical Commission, which gran-
ted the approval.
The clearances were determined according to the procedure
described earlier [6–8]. The method was based on a multisampling
procedure; the first test was made with 99mTc-HEPIDA, and another
was made two days later using 99mTc-MBrIDA for the same purpose.
The last blood sample was taken at 90 minutes post administration
of radiopharmaceuticals; the urine was collected immediately, and
after urine voiding the fraction of the latter retained in the bladder was
determined by ultrasonographic method. The activity of both radiop-
harmaceuticals was determined by measuring the volume of urine
voided and by measuring the concentration of activity in 1 ml of urine;
the activity measurements were made using the Wizard System. The
urinary clearance was calculated from voided activity and integrated
plasma concentration of the 99mTc activity of each compound from
injection to the time of voiding. The hepatic clearance of each radiop-
harmaceutical was obtained from subtraction of renal clearance from
the corresponding plasma clearance.
The hepatic clearance was normalized to body surface de-
rived from height and mass of the body using the formula of
Haycock.
In each patient, the following biochemical tests were made (not
later than 2 days after determination of the clearance) in the se-
rum: bilirubin conc., activity of ALT, AST, and GGTP, concentration
of albumin and gamma globulin, protrombine index, and serum
proteinogram.
Over these two days, no changes in the clinical status were
observed and no event was noted that could affect the functional
status of the liver in the studied individuals.
Statistical processing of the data
The results of 99mTc-HEPIDA clearances were correlated with
those obtained from 99mTc-MBrIDA investigations and the regres-
sion lines were obtained by means of orthogonal least square
method.
The functional state of liver parenchyma was derived from the
results of the laboratory tests of the seven above-mentioned bio-
chemical indices. For purpose of evaluation, an algorithm, as de-
fined by Białkowska and co-workers [3, 4] and further modified by
Frieske et al. [9, 10], was used. Summarizing briefly the idea of the
algorithm, there were 4 sub-ranges of each of the test values de-
fined (based on the statistical distribution of the results for the test).
A number (0 to 3) was attributed to the sub-ranges, resulting from
the position of the data in the sub-ranges. The sub-ranges for all
biochemical indices and corresponding numbers of points attrib-
uted are presented in Table 1.
Table 1. Weight for results of biochemical tests as depending on the measured values
AST [U/l] ALT [U/l] GGTP [U/l] Concentration Concentration Concentration Protrombine Sum of points
of bilirubin [mg/dl] of albumin [mg/dl] of Gglob [mg/dl] index (%) (SP)
1.10.1941 1.08.1935 M: 11–49 do 1.2 > 3.5 do 1.5 80–120 0
F: 7–32
42–99 36–99 M: 50–99 1.2–1.9 3.5–3.16 1.51–2 60–79 1
F: 33–99
100–300 100–300 100–200 2–3 3.15–2.8 2.01–2.5 40–59 2
> 300 > 300 > 200 > 3 < 2.8 > 2.5 < 40 3
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For each of the patients, the sum of weight numbers (SP) was
thus obtained, and all of them were subsequently correlated with
clearance values. As a measure of correlation, the r coefficient of
Spearman was used.
The sum of weight numbers (SP) allowed attribution of the in-
vestigated individuals into 4 groups: group 1, SP = 0 — no da-
mage to the hepatic parenchyma; group 2, SP = 1–5 — marginal
damage to the liver parenchyma; group 3, SP = 6–10 — substan-
tial damage to the liver parenchyma; and group 4, SP > 10
— severe liver parenchyma damage.
Such a division of patients into 4 groups, and division of clear-
ance values into 3 equal sub-ranges enabled application of the c2
test of independence of the attributes, i.e. of biochemical evalua-
tion and results of clearance determinations.
Utilization of all measured values made possible a factorial
analysis with the aim of finding a common factor, named here liver
performance, and to attribute a load of each measured quantity to
the performance. For this purpose, Statistica software was used.
Results
The values of plasma-hepatic and urinary clearances while
using the two radiopharmaceuticals, as observed in the studied
individuals and contained in the above-defined ranges, are pre-
sented in Table 2.
In Figure 1, the distributions of urinary clearances for the two
radiopharmaceuticals are presented. It may be seen that urinary
clearances of 99mTc-MBrIDA are much lower than the correspond-
ing clearances of 99mTc-HEPIDA.
Figures 2 and 3 present correlations between plasma and he-
patic clearances for the two radiopharmaceuticals. Figure 4 pre-
sents the correlation between 99mTc-HEPIDA hepatic and
99mTc-MBrIDA plasmatic clearances. There is obvious correlation
between the mentioned quantities.
Figures 5 and 6 show a correlation between sums of weight
points obtained from biochemical studies and corresponding plas-
ma and hepatic clearances (99mTc-HEPIDA and 99mTc-MBrIDA).
These graphs and values of the Spearman correlation coefficients
confirm that these values are correlated.
In Table 3 the clearance values and values of the c2 test of in-
dependence of the group of patients are assembled.
Using two radiopharmaceuticals, the classification of patients
with different degrees of liver parenchyma damage is very si-
milar (see Table 4). The highest c2 value was obtained for the
hepatic 99mTc-HEPIDA clearance, and the lowest was for plas-
ma clearance for the same substance. The remaining c2 values
for 99mTc-MBrIDA are identical. The obtained c2 values speak for
rejection (p > 0.05) of the hypothesis that the clearance values
and the results of the biochemical tests are independent of each
other.
Table 2. The lowest and highest values in 3 types of clearances determined in the studied patients, using 99mTc-HEPIDA and 99mTc-MBrIDA
The lowest and highest values of clearances [ml/min]
99mTc-HEPIDA 99mTc-MBrIDA
Plasma Hepatic Urinary Plasma Hepatic Urinary
Max 251.3 197.5 102.5 449.4 440 13.6
Min 75.7 17.8 19.7 52.7 48.7 2.2
Figure 1. Histograms of urinary clearances of 99mTc-HEPIDA and 99mTc-MBrIDA.
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In Table 5, the factor loadings for hepatic performance have
been assembled (biochemical tests, clearances of both radiop-
harmaceuticals). The results are in agreement with those of the
correlation studies and c2 tests. It should be mentioned that the
highest factor loadings contribute the hepatic and plasmatic
99mTc-HEPIDA clearances; the values of two loadings of 99mTc-MBr-
IDA clearances are very close, but clearly somewhat lower than
those for 99mTc-HEPIDA are.
The factor loadings of individual biochemical tests are evident-
ly much lower.
Discussion
For years, 99mTc-HEPIDA was used for hepatic clearance de-
termination. The usefulness of this radiopharmaceutical for the as-
sessment of hepatic parenchyma performance by determination
of hepatic clearance had been documented in earlier publications
[2–4, 9–11]. It was demonstrated that hepatic clearance is superi-
or for this purpose than plasma clearance is [9–11]. The results of
the hepatic clearance determination, as observed in the present
study, are in full agreement with the previous studies. This test has
Figure 2. Correlation and regression line between plasma clearances
of 99mTc-HEPIDA  and 99mTc-MBrIDA.
Figure 3. Correlation and regression line between hepatic clearances
of 99mTc-HEPIDA  and 99mTc-MBrIDA.
Figure 4. Correlation and regression line between hepatic clearance
of 99mTc-HEPIDA  and plasma clearance of 99mTc-MBrIDA.
Figure 5. Correlation of Sum of points and clearances of  99mTc-HEPIDA:
¥ and dashed line–plasma,∑and solid line–hepatic.
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therefore been selected as a standard for comparison with
99mTc-BrIDA clearances.
As may be seen in Figure 2, the average value of urinary clear-
ance of 99mTc-HEPIDA is ab. 50 ml/min; however, distribution of
this quantity is wide with a standard deviation = 14 ml/min. This
flat distribution with high variation coefficient indicates that, in
a single patient, finding a value of this clearance in the range from
30 ml/min to 60 ml/min is almost equally probable and cannot be
guessed in advance.
In contrast, as can be seen in Figure 1, the distribution of
urinary clearances of 99mTc-MBrIDA is very narrow and on aver-
age equals 5.6 ml/min with s = 2.3 ml/min. Such a narrow distri-
bution justifies the expectation that urinary clearance in an indi-
vidual patient is easy to predict. By subtracting this average va-
lue from the plasma clearance one can obtain the hepatic clear-
ance of 99mTc-MBrIDA. The probable error (two standard devia-
tions — 5 ml/min) will not have any serious impact on the inter-
pretation of the hepatic clearance. This situation justifies resig-
nation of urine collection and determination of the urinary clear-
ance of 99mTc-MBrIDA.
There are also further justifications for determination of
99mTc-MBrIDA clearance only. Thus:
1. Plasma clearance of 99mTc-MBrIDA correlates more closely with
99mTc-HEPIDA hepatic clearance than with the hepatic
Table 3. The c2 values of the test for independence of clearance re-
sults and grouping of patients on the basis of biochemical tests





Table 4. Classification of patient groups as related to ranges of he-
patic 99mTc-HEPIDA and plasmatic 99mTc-MBrIDA clearances
Clearance range Group of patients acc. to classification
[ml/min/1.73 m2]  based on biochemical tests
0 1 2 + 3
99mTc-HEPIDA
£ 129 1 8 6
129 <…£ 177 7 26 6
177 < 6 13 0
99mTc-MBrIDA
£ 150 2 16 5
150 <...£ 250 10 22 6
250 < 2 9 1
Table 5. Values of factor loading for “Liver performance”, as observed
for individual tests
The diagnostic test Value of factor loading
99mTc-HEPIDA Hepatic clearance 0.901487
99mTc-HEPIDA Plasma clearance 0.877251
99mTc-MBrIDA Hepatic clearance 0.833514
99mTc-MBrIDA Plasma clearance 0.828202








Figure 6. Correlation of Sum of points and clearances of  99mTc-MBrIDA:
¥ and dashed line–plasma,∑and solid line–hepatic.
99mTc-MBrIDA clearance (Figures 2 and 3). This results most
likely from the fact that hepatic clearances are calculated as
the difference between the plasma and corresponding urinary
clearances. This subtraction results in propagation of errors
and therefore the error of 99mTc-BrIDA hepatic clearance is sub-
ject to greater error than the corresponding plasma clearance
alone. This is the reason for the fact that 99mTc-MBrIDA clear-
ance is more widely scattered around the regression line than
the plasmatic clearance of this substance.
2. The c2 test indicates that both the plasma and hepatic clear-
ance of 99mTc-MBrIDA display the same agreement with da-
mage to hepatic parenchyma, as based on biochemical tests.
This justifies selecting the more simple determination of the
two.
3. A negligible difference between the factor loadings of both
99mTc-MBrIDA clearances implies that they are equally suited
for assessment of liver performance.
These preliminary studies demonstrated that 99mTc-MBrIDA
clearances reflect the functional state of liver parenchyma; how-
ever, their factor loading is somewhat smaller than that of
99mTc-HEPIDA, and correlations of the former with the sum of
the points of biochemical assessment are less close (Figures 5
and 6, Table 3). Nevertheless, these differences do not appear
to be substantial.
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Conclusions
1. 99mTc-MBrIDA clearances may be used for evaluation of liver
parenchyma performance, despite the fact that the results may
not be as certain as those obtained using 99mTc-HEPIDA for the
same purpose.
2. The results of this study seem quite convincing that for evalua-
tion of liver performance, plasma clearance of 99mTc-MBrIDA is
sufficient.
3. Further studies of the clinical usefulness of 99mTc-MBrIDA plas-
ma clearance seem advisable.
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